Cost-effectiveness of novel vaccines for tuberculosis control: a decision analysis study.
BACKGROUND
The development of a successful new tuberculosis (TB) vaccine would circumvent many limitations of current diagnostic and treatment practices. However, vaccine development is complex and costly. We aimed to assess the potential cost effectiveness of novel vaccines for TB control in a sub-Saharan African country--Zambia--relative to the existing strategy of directly observed treatment, short course (DOTS) and current level of bacille Calmette-Guérin (BCG) vaccination coverage.


METHODS
We conducted a decision analysis model-based simulation from the societal perspective, with a 3% discount rate and all costs expressed in 2007 US dollars. Health outcomes and costs were projected over a 30-year period, for persons born in Zambia (population 11,478,000 in 2005) in year 1. Initial development costs for single vaccination and prime-boost strategies were prorated to the Zambian share (0.398%) of global BCG vaccine coverage for newborns. Main outcome measures were TB-related morbidity, mortality, and costs over a range of potential scenarios for vaccine efficacy.


RESULTS
Relative to the status quo strategy, a BCG replacement vaccine administered at birth, with 70% efficacy in preventing rapid progression to TB disease after initial infection, is estimated to avert 932 TB cases and 422 TB-related deaths (prevention of 199 cases/100,000 vaccinated, and 90 deaths/100,000 vaccinated). This would result in estimated net savings of $3.6 million over 30 years for 468,073 Zambians born in year 1 of the simulation. The addition of a booster at age 10 results in estimated savings of $5.6 million compared to the status quo, averting 1,863 TB cases and 1,011 TB-related deaths (prevention of 398 cases/100,000 vaccinated, and of 216 deaths/100,000 vaccinated). With vaccination at birth alone, net savings would be realized within 1 year, whereas the prime-boost strategy would require an additional 5 years to realize savings, reflecting a greater initial development cost.


CONCLUSIONS
Investment in an improved TB vaccine is predicted to result in considerable cost savings, as well as a reduction in TB morbidity and TB-related mortality, when added to existing control strategies. For a vaccine with waning efficacy, a prime-boost strategy is more cost-effective in the long term.
Respiratory Epidemiology and Clinical Research Unit, Montreal Chest Institute, Montreal, Canada.
Chia-Lin
CL
Tseng
Olivia
O
Oxlade
Dick
D
Menzies
Anne
A
Aspler
Kevin
K
Schwartzman
D000293:Adolescent; D000328:Adult; D001500:BCG Vaccine / Q000191:economics / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D003140:Communicable Disease Control / Q000191:economics*; D017281:Cost of Illness; D003362:Cost-Benefit Analysis; D003661:Decision Support Techniques; D023801:Directly Observed Therapy; D017048:Health Care Costs / Q000706:statistics & numerical data; D005102:Health Expenditures / Q000706:statistics & numerical data; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D014376:Tuberculosis / Q000191:economics / Q000517:prevention & control*; D032581:Tuberculosis Vaccines / Q000191:economics / Q000627:therapeutic use*; D055815:Young Adult; D015024:Zambia
D001500:BCG Vaccine; D032581:Tuberculosis Vaccines
AIDS. 2000 Nov 10;14(16):2515-21
11101063
Am J Respir Crit Care Med. 1996 Oct;154(4 Pt 1):1034-8
8887603
Lancet Infect Dis. 2009 Mar;9(3):162-72
19246020
Lancet. 1995 Aug 26;346(8974):581
7658805
AIDS. 2002 Mar 8;16(4):597-603
11873003
J Immunol. 2004 Nov 15;173(10):6357-65
15528375
Int J Epidemiol. 1993 Dec;22(6):1154-8
8144299
N Engl J Med. 2005 Sep 8;353(10):1008-20
16148286
JAMA. 1994 Mar 2;271(9):698-702
8309034
AIDS. 1993 Oct;7(10):1345-9
8267907
Ann Intern Med. 1995 Jun 15;122(12):906-12
7755225
Emerg Infect Dis. 2006 Sep;12(9):1389-97
17073088
Int J Tuberc Lung Dis. 2005 Oct;9(10):1147-54
16229227
Vaccine. 2007 Jan 2;25(1):14-8
16959383
N Engl J Med. 1993 Apr 22;328(16):1137-44
8096066
Lancet. 2004 Mar 6;363(9411):814-9
15016493
J Bioeth Inq. 2009 Jun;6(2):219-228
19536332
Am Rev Respir Dis. 1981 Feb;123(2):165-70
7015933
JAMA. 2004 May 5;291(17):2086-91
15126436
Int J Tuberc Lung Dis. 2005 May;9(5):521-7
15875923
Clin Infect Dis. 2000 Sep;31 Suppl 3:S64-7
11010824
Curr Opin Immunol. 2006 Aug;18(4):438-48
16777396
Wkly Epidemiol Rec. 2007 May 25;82(21):193-6
17526121
Am J Respir Crit Care Med. 1998 Apr;157(4 Pt 1):1249-52
9563747
Bull World Health Organ. 2007 May;85(5):327
17639210
Int J Tuberc Lung Dis. 1997 Feb;1(1):68-74
9441062
Lancet. 2002 Aug 17;360(9332):528-34
12241657
Infect Immun. 2001 Apr;69(4):2714-7
11254639
Nat Rev Microbiol. 2006 Jun;4(6):469-76
16710326
Bull Int Union Tuberc. 1975;50(1):90-106
1218291
Lancet. 1980 May 31;1(8179):1182-3
6103997
JAMA. 2000 May 17;283(19):2537-45
10815117
Am Rev Respir Dis. 1974 Nov;110(5):572-80
4429253
Int J Tuberc Lung Dis. 1997 Oct;1(5):446-53
9441100
N Engl J Med. 1992 Jan 23;326(4):231-5
1345800
BMC Public Health. 2006 Aug 15;6:209
16911786
AIDS. 2001 Sep 28;15(14):1875-9
11579251
J Immunol. 2003 Aug 1;171(3):1602-9
12874255
Int J Tuberc Lung Dis. 2008 Aug;12(8):928-35
18647453
Am J Respir Crit Care Med. 2000 Dec;162(6):2079-86
11112118
Med Decis Making. 2003 Jan-Feb;23(1):76-82
12583457
Int J Tuberc Lung Dis. 2001 Jan;5(1):24-31
11263512
Am Rev Respir Dis. 1984 Jun;129(6):921-8
6375490
Int J Health Plann Manage. 2002 Jul-Sep;17(3):249-67
12298146
Int J Tuberc Lung Dis. 1999 Dec;3(12):1088-95
10599012
N Engl J Med. 1997 Sep 18;337(12):801-8
9295239
Int J Tuberc Lung Dis. 2000 Feb;4(2):133-8
10694091
Lancet. 2001 Nov 17;358(9294):1687-93
11728545
Can J Public Health. 1997 May-Jun;88(3):197-201
9260361
Lancet. 2006 Apr 8;367(9517):1173-80
16616560
J Acquir Immune Defic Syndr. 2000 Jan 1;23(1):75-80
10708059
Int J Tuberc Lung Dis. 1998 Mar;2(3):235-41
9526197
Bull Int Union Tuberc. 1978 Jun;53(2):70-5
737353
Proc Natl Acad Sci U S A. 2009 Aug 18;106(33):13980-5
19666590
Arch Intern Med. 1997 Jan 27;157(2):227-32
9009982
AIDS. 2006 Apr 4;20(6):915-21
16549977
Ann Intern Med. 1992 Aug 1;117(3):177-83
1616211
JAMA. 1992 Sep 9;268(10):1280-6
1507374
Am Rev Respir Dis. 1969 Feb;99(2):183-93
5767002
JAMA. 1996 Oct 16;276(15):1253-8
8849754
Bull World Health Organ. 2008 Jan;86(1):20-6
18235886
Lancet. 1995 Nov 18;346(8986):1339-45
7475776
Am J Respir Crit Care Med. 1999 Mar;159(3):733-40
10051244
Proc Natl Acad Sci U S A. 2008 Oct 21;105(42):16302-7
18849476
Am J Respir Crit Care Med. 2009 Apr 15;179(8):724-33
19151191
Am J Public Health. 2001 Jan;91(1):138-41
11189809
J Theor Biol. 2008 Oct 7;254(3):633-49
18644386
Pediatrics. 1995 Jul;96(1 Pt 1):29-35
7596718
Am Rev Respir Dis. 1977 Jul;116(1):3-8
69411
Ann Intern Med. 1990 Mar 15;112(6):407-15
2106816
N Engl J Med. 1992 Jun 4;326(23):1514-21
1304721
Int J Tuberc Lung Dis. 2000 Jun;4(6):496-503
10864179
Am Rev Respir Dis. 1986 Jul;134(1):27-33
3524334
Am Rev Respir Dis. 1988 Apr;137(4):805-9
3354985
Emerg Infect Dis. 2004 Sep;10(9):1529-35
15498152
J Infect Dis. 2006 Aug 15;194(4):479-85
16845631
Immunol Cell Biol. 2009 May-Jun;87(4):279-86
19350048
Am Rev Respir Dis. 1986 May;133(5):779-83
2871788